Ericka Vélez-Bonet

Ericka Vélez-Bonet

Auto-generated profile, based on publicly available information

Ericka Vélez-Bonet

The Ohio State University Wexner Medical Center 1 Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition Columbus, Ohio

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
VGValentina Pita Grisanti
Valentina Pita Grisanti
EVEricka Velez-Bonet
Ericka Velez-Bonet
KCKaylin Chasser
Kaylin Chasser
ZHZachary Hurst
Zachary Hurst
ALAlexus Liette
Alexus Liette
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Obesity is a risk factor for pancreatic ductal adenocarcinoma (PDAC), a deadly disease with limited preventive strategies. Lifestyle interventions to decrease obesity represent a potential approach to prevent obesity-associated PDAC. In this study, we examined whether decreasing obesity through physical activity (PA) and/or dietary changes could decrease inflammation in humans and prevent obesity-associated PDAC in mice. Comparison of circulating inflammatory-associated cytokines in subjects (overweight and obese) before and after a PA intervention revealed PA lowered systemic inflammatory cytokines. Mice with pancreatic-specific inducible KrasG12D expression were exposed to PA and/or dietary interventions during and after obesity-associated cancer initiation. In mice with concurrent diet-induced obesity and KrasG12D expression, the PA intervention led to lower weight gain, suppressed systemic inflammation, delayed tumor progression, and decreased proinflammatory signals in the adipose tissue. However, these benefits were not as evident when obesity preceded pancreatic KrasG12D expression. Combining PA with diet-induced weight loss (DI-WL) delayed obesity-associated PDAC progression in the genetically engineered mouse model, but neither PA alone nor combined with DI-WL or chemotherapy prevented PDAC tumor growth in orthotopic PDAC models regardless of obesity status. PA led to the upregulation of Il15ra in adipose tissue. Adipose-specific overexpression of Il15 slowed PDAC growth but only in nonobese mice. Overall, our study suggests that PA alone or combined with DI-WL can reduce inflammation and delay obesity-associated PDAC development or progression. Lifestyle interventions that prevent or manage obesity or therapies that target weight loss–related molecular pathways could prevent progression of PDAC. Significance: Physical activity reduces inflammation and induces changes to adipose-related signaling to suppress pancreatic cancer, supporting the potential of obesity management strategies to reduce the risk of developing pancreatic cancer. See related commentary by Sogunro and Muzumdar, p. 2935

14 December 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
EVEricka Vélez-Bonet
Ericka Vélez-Bonet
KGKristyn Gumpper-Fedus
Kristyn Gumpper-Fedus
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Although there has been a long-standing connection between hyperinsulinemia and cancer development, there is a lack of understanding of the role of the insulin receptor on cells that can become cancerous. In a recent issue of Cell Metabolism, Zhang and colleagues, using a diet-induced obesity mouse model, identified a direct function of insulin receptors on pancreatic acinar cells expressing a KRASG12D mutation in promoting obesity-associated pancreatic cancer. Furthermore, insulin receptor signaling from hyperinsulinemia promoted the secretion of digestive enzymes that contributed to acinar to ductal metaplasia. These findings highlight an important connection between obesity, diabetes, and pancreatic tumor development and suggest potential strategies for obesity-associated cancer prevention targeting the insulin receptor signaling pathways.

26 June 2026 in Cancer Research
Verified
Journal Article
Closed access
EVEricka Vélez-Bonet
Ericka Vélez-Bonet
KGKristyn Gumpper-Fedus
Kristyn Gumpper-Fedus
KCKaylin M. Chasser
Kaylin M. Chasser
ZHZachary A. Hurst
Zachary A. Hurst
ATAdaliz Torres-Rosado
Adaliz Torres-Rosado
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes. Obesity increases the risk of PDAC through metabolic dysregulation and inflammation. Ketogenic diet (KD) can alter metabolism and has been evaluated for its effects on tumor progression in nonobese PDAC using genetically engineered mouse models (GEMM). We hypothesized that KD may also prevent obesity-associated PDAC progression by altering body composition and cancer metabolism. Therefore, male PDAC GEMMs were subjected to diet-induced obesity (DIO) using high-fat diets or maintained on a low-fat diet (LFD) for 15 weeks. Mice were then randomized to continue the initial diets or switch to a KD or matched control diet for 6 weeks. Body weight and composition, glucose tolerance, ketone levels, pancreas histology, and tissue metabolomics were assessed. Furthermore, murine pancreas-derived organoids from DIO or LFD-fed GEMMs were treated with a ketone body and analyzed using untargeted metabolomics. In obese PDAC GEMMs, KD delayed cancer progression independent of weight loss, an effect not observed in nonobese LFD-fed mice. KD-mediated PDAC suppression was associated with enrichment of pancreatic metabolic pathways that support nonglucose energy production. Ketone-treated organoids recapitulated a subset of the KD-associated metabolic differences observed in vivo, suggesting a direct metabolic effect on cancer cells. These findings suggest potential benefits of a KD in preventing obesity-associated PDAC. The diet–cancer metabolic interactions highlight potential opportunities for dietary or metabolic interventions to prevent PDAC in high-risk obese populations. Significance: Ketogenic diet prevents pancreatic cancer progression in obese, but not in nonobese, genetically engineered mouse models and modifies pancreatic metabolic pathways, informing future dietary and therapeutic strategies for high-risk obese populations.

24 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EVEricka Vélez-Bonet
Ericka Vélez-Bonet
KGKristyn Gumpper-Fedus
Kristyn Gumpper-Fedus
KCKaylin Chasser
Kaylin Chasser
ZHZachary Hurst
Zachary Hurst
HHHsiang-Yin Hsueh
Hsiang-Yin Hsueh
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes. Obesity is a risk factor for several cancers including PDAC due to metabolic dysregulation and inflammation. The ketogenic diet (KD) can alter metabolism and has been evaluated for its effects on tumor progression in non-obese but not obese PDAC using genetically engineered mouse models (GEMMs). We hypothesized that ketone bodies and a KD alter cell and tumor metabolism. We show that ketone treatments altered pyrimidine metabolism in PDAC cells. Moreover, in an obese PDAC GEMM, KD prevented tumor progression independent of weight loss but promoted PDAC in a non-obese PDAC GEMM. The KD-specific delay of obesity-associated PDAC was associated with pancreatic metabolic shifts in pyrimidine, cysteine and methionine, and arginine and proline pathways. These findings suggest potential benefits of a KD in preventing obesity-associated PDAC, but highlights some risks in non-obese settings.

17 June 2026
Verified
Other
Open access
VGValentina Pita Grisanti
Valentina Pita Grisanti
EVEricka Velez-Bonet
Ericka Velez-Bonet
KCKaylin Chasser
Kaylin Chasser
ZHZachary Hurst
Zachary Hurst
ALAlexus Liette
Alexus Liette
ZCZobeida Cruz-Monserrate
Zobeida Cruz-Monserrate
Supplementary Materials and Methods - Clean